<p>The median and range are shown. Lymphoid cells were gated according to their FSC/SSC profile.</p><p>Immune cell subpopulations in MS patients before (t0) or after three months of fingolimod treatment (t3) and healthy controls analysed by <i>ex vivo</i> flow cytometry.</p
<p>Effects of fingolimod on peripheral blood lymphocyte counts (A) and absolute numbers and percenta...
Objective:Fingolimod is approved for the treatment of highly active relapsing remitting multiple scl...
<p>Total number (×10<sup>3</sup> cells/µl blood) of lymphocytes, T cells and B cells in treatment-na...
<p>PBMCs of MS patients before (t0, n = 16) or after three months of treatment by fingolimod (t3, n ...
We investigated, lymphocyte count (LC) and lymphocyte subpopulations (LS) in a real life setting of ...
<div><p>Background and objective</p><p>The long term effects of fingolimod, an oral treatment for re...
Objective: To establish cytometry profiles associated with disease stages and immunotherapy in MS. M...
<p>Effects of fingolimod on phenotypically distinct CD4<sup>+</sup>T (A) and CD8<sup>+</sup>T (B) ce...
<p>(A) CD19<sup>+</sup> B cell subtype proportion and (B) CD4<sup>+</sup> T cell subtype proportion ...
<p>Regulatory T cells of MS patients before (t0, n = 16) or after three months of treatment by fingo...
Peripheral blood biomarkers able to predict disease activity in multiple sclerosis (MS) patients hav...
<p>Effects of fingolimod on IFNγ- (A), IL17- (B), IL9- (C), and IL4-producing (D) cells in CD4<sup>+...
<p>(A.) Percentage of PB follicular helper T cells (T<sub>FH</sub>) in MS patients treated with fing...
BACKGROUND:Treatment with fingolimod reduces inflammation in multiple sclerosis (MS) by inhibiting l...
BackgroundFingolimod is a sphingosine 1-phosphate receptor modulator approved for relapsing MS. Long...
<p>Effects of fingolimod on peripheral blood lymphocyte counts (A) and absolute numbers and percenta...
Objective:Fingolimod is approved for the treatment of highly active relapsing remitting multiple scl...
<p>Total number (×10<sup>3</sup> cells/µl blood) of lymphocytes, T cells and B cells in treatment-na...
<p>PBMCs of MS patients before (t0, n = 16) or after three months of treatment by fingolimod (t3, n ...
We investigated, lymphocyte count (LC) and lymphocyte subpopulations (LS) in a real life setting of ...
<div><p>Background and objective</p><p>The long term effects of fingolimod, an oral treatment for re...
Objective: To establish cytometry profiles associated with disease stages and immunotherapy in MS. M...
<p>Effects of fingolimod on phenotypically distinct CD4<sup>+</sup>T (A) and CD8<sup>+</sup>T (B) ce...
<p>(A) CD19<sup>+</sup> B cell subtype proportion and (B) CD4<sup>+</sup> T cell subtype proportion ...
<p>Regulatory T cells of MS patients before (t0, n = 16) or after three months of treatment by fingo...
Peripheral blood biomarkers able to predict disease activity in multiple sclerosis (MS) patients hav...
<p>Effects of fingolimod on IFNγ- (A), IL17- (B), IL9- (C), and IL4-producing (D) cells in CD4<sup>+...
<p>(A.) Percentage of PB follicular helper T cells (T<sub>FH</sub>) in MS patients treated with fing...
BACKGROUND:Treatment with fingolimod reduces inflammation in multiple sclerosis (MS) by inhibiting l...
BackgroundFingolimod is a sphingosine 1-phosphate receptor modulator approved for relapsing MS. Long...
<p>Effects of fingolimod on peripheral blood lymphocyte counts (A) and absolute numbers and percenta...
Objective:Fingolimod is approved for the treatment of highly active relapsing remitting multiple scl...
<p>Total number (×10<sup>3</sup> cells/µl blood) of lymphocytes, T cells and B cells in treatment-na...